Logo

MGTX

MeiraGTx Holdings plc

MGTX

MeiraGTx Holdings plc • NASDAQ
$8.30 ▲ 1.22% (+0.10)
Market Cap $668.07 M
52w High $9.73
52w Low $4.55
Dividend Yield 0%
P/E -3.93
Volume 276.67K
Outstanding Shares 80.49M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $410K ▼ $46.148M ▲ $-50.513M ▼ -12.32K% ▼ $-0.62 ▼ $-44.01M ▼
Q2-2025 $3.691M ▲ $45.808M ▲ $-38.795M ▲ -1.051K% ▲ $-0.48 ▲ $-32.571M ▲
Q1-2025 $1.926M ▼ $42.144M ▲ $-39.981M ▼ -2.076K% ▼ $-0.51 ▼ $-33.857M ▼
Q4-2024 $21.39M ▲ $41.074M ▲ $-39.399M ▼ -184.194% ▲ $-0.5 ▲ $-33.064M ▼
Q3-2024 $10.91M $38.966M $-39.33M -360.495% $-0.55 $-32.713M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $14.841M ▼ $189.471M ▼ $230.028M ▲ $-40.557M ▼
Q2-2025 $32.166M ▼ $198.716M ▼ $195.756M ▲ $2.96M ▼
Q1-2025 $66.523M ▼ $224.014M ▼ $190.915M ▼ $33.099M ▼
Q4-2024 $103.659M ▼ $269.751M ▼ $201.924M ▼ $67.827M ▼
Q3-2024 $122.873M $299.488M $203.752M $95.736M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-50.513M ▼ $-12.215M ▲ $-547K ▲ $-219K ▼ $-17.318M ▲ $-12.825M ▲
Q2-2025 $-38.795M ▲ $-43.947M ▼ $-761K ▲ $5.45M ▲ $-34.186M ▲ $-45.181M ▼
Q1-2025 $-39.981M ▼ $-36.828M ▼ $-1.71M ▼ $1.713M ▼ $-37.058M ▼ $-38.538M ▼
Q4-2024 $-39.399M ▼ $-23.276M ▲ $-1.218M ▲ $4.244M ▼ $-19.361M ▼ $-24.494M ▲
Q3-2024 $-39.33M $-25.022M $-1.314M $49.957M $24.004M $-25.752M

Five-Year Company Overview

Income Statement

Income Statement MeiraGTx is still very much a development‑stage biotech company: revenue is tiny and has not grown in a meaningful way over the past five years. The company runs sizeable operating and net losses every year, reflecting heavy spending on research, clinical trials, and infrastructure. Losses widened again most recently, and earnings per share remain deeply negative, which underscores that the business is far from covering its cost base with current income.

Balance Sheet

Balance Sheet The balance sheet shows a moderate asset base with cash making up a large share, but the cash pool has been shrinking over time. Debt has crept up from very low levels, while shareholders’ equity has been moving down, indicating that accumulated losses are eating into the company’s capital. Overall, the financial cushion is not huge relative to ongoing spending, so the company looks dependent on external funding, milestone receipts, or new partnerships to sustain its programs over the medium term.

Cash Flow

Cash Flow Operating cash flow has been consistently negative, which is expected for a company without commercial products but highlights meaningful ongoing cash burn. Free cash flow is also firmly negative year after year, driven by both operating losses and prior years’ investment in facilities and equipment. While capital spending has eased from its peak, the business still consumes cash and will likely need periodic infusions to support its clinical pipeline and manufacturing platform.

Competitive Edge

Competitive Edge Despite weak current financials, MeiraGTx has built a differentiated position in gene therapy through its specialized technology, manufacturing control, and late‑stage programs. The proprietary riboswitch platform and advanced AAV engineering, along with fully integrated in‑house manufacturing, give it tools many peers lack and can shorten timelines and reduce dependency on third parties. Strategic alliances with large pharmaceutical partners such as Johnson & Johnson and Eli Lilly validate its science and help offset some development risk, but the company still faces intense competition, regulatory uncertainty, and execution risk common to cutting‑edge biotech.

Innovation and R&D

Innovation and R&D The company is very R&D‑heavy, channeling substantial resources into a broad pipeline in neurology, ophthalmology, and other areas, plus its riboswitch gene‑regulation platform. It has several late‑stage clinical assets targeting serious conditions like Parkinson’s disease, inherited retinal disorders, and radiation‑induced dry mouth, alongside earlier programs in metabolic and immune diseases. This creates many potential future value drivers but also concentrates risk in clinical and regulatory outcomes and lengthens the path to meaningful commercial revenue.

Summary

MeiraGTx is a high‑innovation, high‑risk gene therapy company with minimal current revenue and sizable recurring losses. Its financial profile shows ongoing cash burn, a shrinking equity base, and a need for continuing access to outside capital, milestone payments, or new deals. At the same time, it holds notable scientific and strategic assets: proprietary gene‑regulation technology, integrated manufacturing, and partnerships with major pharma companies, plus multiple late‑stage trials. The company’s future will be shaped largely by clinical data, regulatory decisions, and its ability to convert its technology and collaborations into sustainable, commercial‑scale income, with considerable uncertainty around timing and ultimate success.

NEWS

November 20, 2025 · 3:00 PM UTC

Graviton Bioscience to Present Selective ROCK2 Obesity Data at 8th Annual Evercore HealthCONx Conference

Read more

November 13, 2025 · 8:00 AM UTC

MeiraGTx Reports Third Quarter 2025 Financial and Operational Results

Read more

November 10, 2025 · 7:00 AM UTC

MeiraGTx Enters into Strategic Collaboration with Eli Lilly and Company to Develop and Commercialize Genetic Medicines in Ophthalmology

Read more

October 7, 2025 · 8:00 AM UTC

MeiraGTx Announces Two Posters at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress

Read more